Literature DB >> 19661269

Dominant role of CD47-thrombospondin-1 interactions in myeloma-induced fusion of human dendritic cells: implications for bone disease.

Anjli Kukreja1, Soroosh Radfar, Ben-Hua Sun, Karl Insogna, Madhav V Dhodapkar.   

Abstract

Lytic bone disease in myeloma is characterized by an increase in multinucleate osteoclasts in close proximity to tumor cells. However, the nature of osteoclast precursors and the mechanisms underlying multinuclearity are less understood. Here we show that culture of myeloma cell lines as well as primary myeloma cells with human dendritic cells (DCs) but not monocytes or macrophages leads to spontaneous cell-cell fusion, which then leads to the facile formation of multinucleate bone-resorbing giant cells. Osteoclastogenesis is cell contact dependent, leading to up-regulation of thrombospondin-1 (TSP-1) in DCs. Disruption of CD47-TSP-1 interaction by TSP-1-blocking antibodies or down-regulation of CD47 on tumor cells by RNA interference abrogates tumor-induced osteoclast formation. Blockade of CD47-TSP-1 interactions also inhibits receptor activator for nuclear factor kappaB ligand- and macrophage colony-stimulating factor-induced formation of osteoclasts from human monocytes. Further, TSP-1 blockade attenuates hypercalcemia induced by parathyroid hormone in vivo. These data point to a role for CD47-TSP-1 interactions in regulating cell-fusion events involved in human osteoclast formation. They also suggest that DCs, known to be enriched in myeloma tumors, may be direct precursors for tumor-associated osteoclasts. Disruption of CD47-TSP-1 interactions or preventing the recruitment of DCs to tumors may provide novel approaches to therapy of myeloma bone disease and osteoporosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19661269      PMCID: PMC2765677          DOI: 10.1182/blood-2009-03-211920

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  52 in total

1.  Human bone marrow myeloma cells express RANKL.

Authors:  Orhan Sezer; Ulrike Heider; Christian Jakob; Jan Eucker; Kurt Possinger
Journal:  J Clin Oncol       Date:  2002-01-01       Impact factor: 44.544

2.  Dendritic cells purified from myeloma are primed with tumor-specific antigen (idiotype) and activate CD4+ T cells.

Authors:  Z Dembic; K Schenck; B Bogen
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

3.  Myeloid neighborhood in myeloma: cancer's underbelly?

Authors:  Madhav V Dhodapkar
Journal:  Am J Hematol       Date:  2009-07       Impact factor: 10.047

Review 4.  Integrin-associated protein (CD47) and its ligands.

Authors:  E J Brown; W A Frazier
Journal:  Trends Cell Biol       Date:  2001-03       Impact factor: 20.808

Review 5.  The cell biology of thrombospondin-1.

Authors:  H Chen; M E Herndon; J Lawler
Journal:  Matrix Biol       Date:  2000-12       Impact factor: 11.583

6.  Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment.

Authors:  N Giuliani; R Bataille; C Mancini; M Lazzaretti; S Barillé
Journal:  Blood       Date:  2001-12-15       Impact factor: 22.113

7.  Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand.

Authors:  J H Han; S J Choi; N Kurihara; M Koide; Y Oba; G D Roodman
Journal:  Blood       Date:  2001-06-01       Impact factor: 22.113

8.  Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression.

Authors:  R N Pearse; E M Sordillo; S Yaccoby; B R Wong; D F Liau; N Colman; J Michaeli; J Epstein; Y Choi
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-18       Impact factor: 11.205

9.  CD47, a ligand for the macrophage fusion receptor, participates in macrophage multinucleation.

Authors:  X Han; H Sterling; Y Chen; C Saginario; E J Brown; W A Frazier; F P Lindberg; A Vignery
Journal:  J Biol Chem       Date:  2000-12-01       Impact factor: 5.157

10.  Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity.

Authors:  T Michigami; N Shimizu; P J Williams; M Niewolna; S L Dallas; G R Mundy; T Yoneda
Journal:  Blood       Date:  2000-09-01       Impact factor: 22.113

View more
  38 in total

Review 1.  Advances in the understanding of myeloma bone disease and tumour growth.

Authors:  Shmuel Yaccoby
Journal:  Br J Haematol       Date:  2010-03-11       Impact factor: 6.998

2.  Lack of CD47 impairs bone cell differentiation and results in an osteopenic phenotype in vivo due to impaired signal regulatory protein α (SIRPα) signaling.

Authors:  Cecilia Koskinen; Emelie Persson; Paul Baldock; Åsa Stenberg; Ingrid Boström; Takashi Matozaki; Per-Arne Oldenborg; Pernilla Lundberg
Journal:  J Biol Chem       Date:  2013-08-29       Impact factor: 5.157

Review 3.  Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma.

Authors:  Masahiro Abe
Journal:  Int J Hematol       Date:  2011-10-18       Impact factor: 2.490

4.  Vesicle transfer and cell fusion: Emerging concepts of cell-cell communication in the tumor microenvironment.

Authors:  T Kevin Howcroft; Huang-Ge Zhang; Madhav Dhodapkar; Suresh Mohla
Journal:  Cancer Biol Ther       Date:  2011-08-01       Impact factor: 4.742

Review 5.  MGUS to myeloma: a mysterious gammopathy of underexplored significance.

Authors:  Madhav V Dhodapkar
Journal:  Blood       Date:  2016-10-13       Impact factor: 22.113

Review 6.  Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics.

Authors:  Antonio Garcia-Gomez; Fermin Sanchez-Guijo; M Consuelo Del Cañizo; Jesus F San Miguel; Mercedes Garayoa
Journal:  World J Stem Cells       Date:  2014-07-26       Impact factor: 5.326

7.  New insights into the molecular pathogenesis of langerhans cell histiocytosis.

Authors:  Francesca M Rizzo; Mauro Cives; Valeria Simone; Franco Silvestris
Journal:  Oncologist       Date:  2014-01-16

Review 8.  Dendritic cells and malignant plasma cells: an alliance in multiple myeloma tumor progression?

Authors:  Marco Tucci; Stefania Stucci; Sabino Strippoli; Franco Dammacco; Franco Silvestris
Journal:  Oncologist       Date:  2011-06-09

9.  Mechanisms of multiple myeloma bone disease.

Authors:  Deborah L Galson; Rebecca Silbermann; G David Roodman
Journal:  Bonekey Rep       Date:  2012-08-01

10.  Thrombospondin-1 regulates bone homeostasis through effects on bone matrix integrity and nitric oxide signaling in osteoclasts.

Authors:  Sarah R Amend; Ozge Uluckan; Michelle Hurchla; Daniel Leib; Deborah Veis Novack; Matthew Silva; William Frazier; Katherine N Weilbaecher
Journal:  J Bone Miner Res       Date:  2015-01       Impact factor: 6.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.